Abstract: The developing fetus is uniquely sensitive to perturbation by chemicals with hormone-like activity.
Introduction
It is well known that perinatal exposure to environmental chemicals with estrogenic activity can have long lasting consequences if exposure occurs during critical periods of development [1] . Recent studies have further proposed that hormonal perturbations during fetal or neonatal development may predispose individuals to disease and/or dysfunction later in life such as hypertension and coronary disease [2] , obesity [3] [4] [5] , and reproductive problems including infertility/subfertility, and increased tumors such as uterine fibroids (leiomyomas) [6] and breast cancer [7] ; also see A. Soto review in this issue. The benign and carcinogenic effects of prenatal exposure to diethylstilbestrol (DES), a potent synthetic estrogen used to prevent miscarriage in the late 1940s-1970s, is an unfortunate reminder of the harmful effects that estrogenic chemicals can cause during development, some of which were not apparent until much later in adulthood or in subsequent generations [8, 9] . Although the use of DES during pregnancy was discontinued over 30 years ago, infants and children continue to be inadvertently exposed to a wide number of environmental chemicals, many with hormone-like activity.
Bisphenol A (BPA), used in the manufacture of polycarbonate plastics and epoxy resins, is one such hormonally active chemical that is receiving increased attention due to its potential for human exposure. BPA has been shown to leach from food cans [10] , beverage containers [11] , and dental sealants and composites [12] , suggesting that humans are routinely exposed to this compound. Experimental animal studies have reported that BPA given during development can act at very low doses in the range of human and wildlife exposures [13] . Further, an increasing number of studies have implicated perinatal BPA exposure in a variety of abnormalities in the female reproductive tract including earlier onset of vaginal opening [14] , early puberty [15] , altered estrus cyclicity [16] , altered plasma LH levels [17] , altered ovarian morphology [16] , and altered body weight [17] . Also, reports of perinatal BPA exposure have been linked to alterations in the mammary gland [18] and uterus [13] but no studies have looked at BPA effects in mature animals exposed as neonates . This study was designed to determine if exposure to BPA at environmentally relevant doses can cause long-term adverse effects in the female reproductive tract in 18 month old animals. 4 
Materials and Methods

Animals:
Adult outbred female CD-1 [Crl:CD-1 (ICR) BR] mice were obtained from Charles River Breeding Laboratories (Raleigh, NC) and bred to male mice of the same strain in the breeding facility at the National Institute of Environmental Health Sciences (NIEHS; Research Triangle Park, NC). Vaginal plug detection was considered day 0 of pregnancy. Pregnant mice were individually housed in plastic cages with hardwood chip bedding under controlled lighting (12 h light and 12 h dark) and temperature (21-22C) conditions. Mice were fed NIH 31 mouse chow, which contained a moderately low amount of genistein (46 µg/g) (14) and fresh water ad libitum.
All animal procedures complied with NIEHS/NIH animal care guidelines. At delivery, pups from all litters were pooled, then separated by sex, and randomly standardized to 8 female pups per dam. (Male pups were used in another experiment.) Female pups were treated by daily subcutaneous injections on days 1-5 with BPA (10, 100, or 1000 µg/kg) dissolved in corn oil or corn oil alone (as Control). These groups are referred to subsequently as BPA-10, BPA-100, BPA-1000 or Control (n=24 female pups per treatment group). These doses were chosen since they were in the range previously reported to cause effects in experimental animals [13, 19] ; also see Richter et al review in this issue. Also, the route of administration, namely subcutaneous injections, is considered relevant for assessing the potential for developmental effects of BPA in humans since newborn mice do not demonstrate the rapid first pass metabolism of BPA as orally dosed adults do (see Richter et al review this issue). Mice were weaned on day 21, housed 4 per cage, and held without further treatment. Mice were sacrificed by CO 2 asphyxiation at 18 months of age. Reproductive tract tissues plus ovaries were removed, fixed in 10% neutral buffered formalin, embedded in paraffin, and sectioned at 6 microns. Tissue sections were stained with hematoxylin and eosin (H & E) and evaluated by light microscopy. If a microscopic lesion was observed, additional serial sections were made to include the entire area of pathological change. Lesions diagnosed as uterine leiomyomas were stained with Masson's trichrome special stain to confirm their smooth muscle cell origin.
Statistical Analysis:
5 Cochran-Armitage trend tests were used to test for dose-related changes in lesion incidence. Lesion incidences in each dose group were separately compared to the Control group incidence using one-sided Fisher's exact tests. P-values < 0.05 were considered statistically significant.
Results
At 18 months of age, body weights were not statistically different between Controls and mice treated neonatally with BPA (54.23 ± 2.10 Controls; 59.99 ± 1.45 BPA-10; 51.62 ± 2.68 BPA-100; and 55.13 ± 2.03 BPA-1000).
A comparison of ovarian and oviductal abnormalities in Control and BPA treated mice is shown in Table 1 . At 18 months, cystic ovaries were common in all treatment groups (39% in Controls, 35% in BPA-10, 70% in BPA-100 and 38% in BPA-1000) but only the BPA-100 in BPA-100, and 6% (1/16) in BPA-1000]. This oviductal abnormality was previously reported in perinatally DES-treated mice [20] and, it histologically resembled the DES lesions; the pattern of tubal plications of oviductal mucosa was often distorted and characterized by irregularities in the size and shape of the mucosal folds relative to the Control animals. The mucosal folds had an adenomatous (gland-like) appearance but maintained connection with the oviductal lumen. This abnormality in proliferation was termed progressive proliferative lesion (PPL) since it did not spread along the serosal surface or metastasize to surrounding tissues [20] .
The range of uterine abnormalities is also shown in Table 1 
Discussion
This report describes the induction of numerous abnormalities in the ovary and reproductive tract of aged female mice treated neonatally with BPA. The doses of BPA chosen were low and within the range of human exposures [13] ; further, these doses have been reported to cause changes in male [23] ; also see vom Saal review in this issue and female mice [13] ; also see A. Soto review in this issue. Skeptics of low dose endocrine disrupting effects criticized early BPA studies because they only described changes in tissues weights and morphology but did not document specific adverse effects. However, more recent studies report adverse effects including premalignant changes in mammary gland tissues [18] and abnormal gene imprinting in the prostate [24, 25] following developmental exposure to BPA. In addition, higher doses of BPA have been shown to cause alterations in estrus cyclicity, ovulation, and ovarian morphology [26] .
Our current study adds to the growing body of literature that reports adverse effects following developmental exposure to low doses of BPA. Our study is the first to show BPA-induced developmental abnormalities in the mature female reproductive tract which include benign, premalignant and neoplastic changes.
Among the significant benign abnormalities was an elevated incidence of ovarian cysts (70% in the BPA-100 group). Although these ovarian cysts are histologically similar to those seen in our aged controls, the incidence is significantly higher (39%). In fact, the incidence is higher than we have seen following developmental exposure to DES .001 mg/kg (58%) [22] , genistein 50 mg/kg (41%) [27] , or tamoxifen (60%) [28] suggesting that the ovary may be a particularly sensitive target for the effects of BPA. Other studies describing the disruption of early oogenesis in the mouse by BPA have also shown the sensitivity of the ovary [29] . Ongoing studies in our laboratory are investigating this possibility as well as mechanisms involved in the formation of ovarian cysts.
Paraovarian cysts of mesonephric (Wolffian) duct origin were also seen in neonatally BPA treated mice in this study. This increased incidence combined with the finding of cystic Wolffian duct remnants in the uterine wall of BPA mice also suggests that the mesonephric duct system (Wolffian duct) may be a target of BPA. Interestingly, mesonephric-derived tissues were noted to be sensitive to the effects of perinatal DES exposure in both male [30] and female mice [31] . 9 Another BPA-induced abnormality that has been described in perinatal DES exposed mice is PPL of the oviduct. DES was previously shown to interfere with the normal differentiation of the Mullerian duct (the precursor of the oviduct) resulting in structural (prenatal exposure) [32] and cellular (neonatal exposure) alterations [20, 33] . A molecular mechanism is likely involved since studies reported that HOX genes were involved in the differentiation of the reproductive tract [34] and prenatal DES was shown to delay the expression of these genes [35] . Subsequent studies suggest DES works through multiple genes pathways [36, 37] . Thus, molecular "misprogramming" is responsible for DES-induced oviductal alterations and is most likely associated with the similar BPA-induced oviductal changes.
The benign lesions of CEH and adenomyosis also occurred in the uterus following neonatal BPA treatment; CEH was statistically increased in the BPA-100 group. These lesions were histologically similar to those seen in aged Controls; however, their severity and the extensive involvement of the uterine horns were increased in BPA treated groups as compared to Controls.
Of particular significance in this study is the occurrence of more severe uterine lesions.
Leiomyomas were seen in all BPA treated groups similar to those seen following DES treatment [38] . Previously, many experimental animal studies examining the tumorigenic potential of environmental estrogens have focused on epithelial lesions of the reproductive tract such as uterine adenocarcinoma [39] ; however, alterations in smooth muscle cells following exogenous estrogen administration have also been shown [21, 40] . Further, we have recently shown an association of prenatal DES exposure in women with the development of uterine leiomyomas [41] . Since smooth muscle lesions are seen in our mice following BPA treatment, it gives validity to the concerns that endocrine disrupting chemicals in the environmental, in particular those with estrogen-like activity, are contributing to the increased incidences of various human diseases; leiomyomas have been proposed to be one such lesion [42] . Although uterine adenocarcinoma was not seen in this study, its premalignant lesion of atypical hyperplasia was observed. Finally, there was an increased incidence of stromal polyps following BPA-100 treatment. These lesions are considered neoplastic in experimental rodent models because they are often the site for the development of endometrial stromal sarcoma [43] . Historically, we have rarely seen these lesions in CD-1 mice although a stromal polyp was seen in one Control mouse in this study. 10 Although adverse effects in the reproductive tract were identified in all BPA treated groups, it is interesting that the BPA-100 dose was the most affected with more leiomyomas, adenomyosis, mesonephric (Wolffian) duct remnants, ovarian cysts, and stromal polyps than the other doses. The significance of this is uncertain but non-linear dose response curves have been commonly reported in endocrinology studies [19] .
In this study, body weights were not different between BPA treated and Control mice. This lack of difference is most likely due to the advanced age of the mice in the study. It has been previously reported by our lab and others that developmental exposure to BPA , DES, and other environmental chemicals with endocrine disrupting effects was associated with obesity in mice after they reach puberty and throughout maturity [3, 4, 44, 45] ; however, these animals were not examined as they aged to 18 months. Since we have also shown that significant differences observed in body weight in DES mice as compared to Controls at 6-8 months get more difficult to detect as the animals age because of increased individual variability among all mice [4] , this variability probably accounts for lack of detection of body weight differences in this study. Most importantly, in this study, there was no apparent correlation of body weight and tumor occurrence either in individual animals or groups.
The findings of the present developmental study raise concerns over BPA contained in products used by infants and children. Further, other studies have shown that BPA transforms Syrian hamster embryo cells (SHE) [46] and induces aneuploidy suggesting that BPA in genotoxic [47] . There is also some evidence of BPA carcinogenicity following adult exposure [48] [49] [50] although the focus of current concern is developmental exposure and long term consequences. Additional studies are needed to determine the potential adverse effects to humans exposed to BPA during critical stages of neonatal or early development. 
